Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Key Points

• Short interest fell sharply: Short interest dropped 22.4% in March to about 15.0 million shares (≈15.4% of shares short) with a short-interest ratio of 8.3 days based on average daily volume.
• Analysts are bullish: Most analysts rate the stock a Buy (two Strong Buy, nine Buy, one Sell) with an average price target of $35.70 versus the recent price near $17.88.
• Clinical-stage biotech with growing institutional ownership: Definium (market cap ≈ $1.78B) is advancing MM120 in Phase 3 and DT402 in Phase 2a, and about 27.9% of the shares are held by hedge funds and institutional investors.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the recipient of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 15,008,738 shares, a drop of 22.4% from the February 26th total of 19,343,010 shares. Based on an average trading volume of 1,813,075 shares, the short-interest ratio is currently 8.3 days. Approximately 15.4% of the shares of the company are short sold.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CenterBook Partners LP bought a new stake in Definium Therapeutics in the 3rd quarter worth approximately $1,880,000. Marshall Wace LLP boosted its stake in Definium Therapeutics by 31.9% in the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company's stock worth $22,204,000 after buying an additional 828,067 shares in the last quarter. Boxer Capital Management LLC bought a new position in Definium Therapeutics during the third quarter valued at approximately $1,928,000. Royce & Associates LP purchased a new position in shares of Definium Therapeutics during the third quarter worth approximately $955,000. Finally, Geode Capital Management LLC raised its stake in shares of Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company's stock worth $11,252,000 after acquiring an additional 66,663 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $17.88 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of -8.39 and a beta of 2.56. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. The business's 50-day moving average price is $17.36 and its two-hundred day moving average price is $14.02. Definium Therapeutics has a twelve month low of $4.70 and a twelve month high of $19.67.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JonesTrading initiated coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a "buy" rating and a $61.00 price target for the company. Jefferies Financial Group started coverage on Definium Therapeutics in a research note on Thursday, January 29th. They issued a "buy" rating and a $30.00 target price for the company. Royal Bank Of Canada lifted their target price on Definium Therapeutics from $20.00 to $36.00 and gave the company an "outperform" rating in a report on Friday, January 23rd. Robert W. Baird set a $37.00 price target on Definium Therapeutics in a research report on Thursday, January 29th. Finally, Wolfe Research assumed coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an "outperform" rating and a $25.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $35.70.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.